This is the first documented comparison of a commercial assay and an LDT on the AltoStar AM16, demonstrating the platform's flexibility, which can enhance laboratory adaptability and capacity to combat the spread of C. auris, a critical fungal pathogen.
Lee et al. (Tue,) studied this question.